Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Korábbi kezelés

• Actionable driver mutation NSCLC patient who has been on anti-bone resorptive therapy
  • Excluded anti-bone resorptive therapy includes: zolendronic acid, pamidronate, alendronate, denosumab or any medication that acts as an osteoclast inhibitor
• Patients with actionable driver mutation who received TKI in past or currently on TKI prior to screening
• Bone metastases that have received prior radiotherapy unless unequivocal progression has occurred since radiation therapy

Más betegség

• Have any condition or illness that, in the opinion of the investigator, would compromise participant safety or interfere with evaluation while on standard of care treatments for the NSCLC.

• Provision to sign and date the consent form
• Stated willingness to comply with all study procedures and be available for the duration of the study
• Be a male or female aged 18-100 years
• Pathologically confirmed non-small cell lung cancer
• Molecular testing through a CLIA-validated NGS assay. This can be done using either tissue based samples or blood-based samples (ctDNA)
• ECOG PS 0-2
• Decision to be on a particular standard of care TKI or chemotherapy +/- immunotherapy (clinical decision that would occur prior to study enrollment)
• Patients who will be treated with an osteoclast inhibitor must receive dental clearance prior to starting treatment
• Bone metastases must be detected through radiographic imaging prior to enrollment on this study.